スコアの説明
- The primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. https://pubmed.ncbi.nlm.nih.gov/38587233/ スコアが高いほうが～
実験群（薬剤）が対照群に優ったこと
- The results for the confirmatory secondary end points favored semaglutide over placebo (estimated between-group difference in change in 6-minute walk distance, 14.3 m [95% CI, 3.7 to 24.9; P = 0.008]; win ratio for hierarchical composite end point, 1.58 [95% CI, 1.29 to 1.94; P<0.001]; and estimated treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80; P<0.001]). https://pubmed.ncbi.nlm.nih.gov/38587233/ 「favor」は他動詞で、〔～の〕方を好む、～への支持を表明する の意味（アルク）。
